IA Mi la·Re ZHa ke, YE Er Deng qieqieke, XIA Yan, PAI Zi lai ti·HA si mu, YANG Li, HAN Rui.
Objective To investigate the expression of serum fibroblast growth factor 21 (FGF-21) and silencing information regulatory factor 6 (SIRT6) in patients with pre-eclampsia (PE) and their relationship with adverse pregnancy outcomes. Methods 132 PE patients from the First Affiliated Hospital of Xinjiang Medical University from January 2022 to December 2024 were selected as the case group, and were divided into PE group (68 cases) and severe PE group (64 cases) according to the severity of their condition. Additionally, 70 healthy pregnant women from the same period were selected as the control group. The expression levels of serum FGF-21 and SIRT6 in the three groups were compared, and Kendall's tau-b correlation coefficient was used to test the correlation between serum FGF-21, SIRT6 and the severity of the disease in PE patients. Based on the pregnancy outcomes of the case group, they were divided into the adverse pregnancy group and the normal pregnancy group. The baseline data of the two groups were compared, and a Logistic regression model was established to focus on analyzing the relationship between the levels of serum FGF-21 and SIRT6 and adverse pregnancy outcomes. Results The serum FGF-21 level was highest in the severe PE group, followed by the PE group, and lowest in the control group (P<0.05). The serum SIRT6 level was the lowest in the severe PE group, followed by the PE group, and the highest in the control group (P<0.05). The severity of PE patients' condition was positively correlated with serum FGF-21 expression levels at the time of enrollment (r>0, P<0.05), and negatively correlated with SIRT6 levels (r<0, P<0.05). At the time of enrollment, the adverse pregnancy group had higher systolic blood pressure, diastolic blood pressure, 24-hour urinary protein, proportion of severe PE, and serum FGF-21 levels than the normal pregnancy group. At the time of enrollment, the serum SIRT6 level was lower than that of the normal pregnancy group (P<0.05). Multivariate Logistic regression analysis showed that regardless of adjusting for confounding factors, serum FGF-21 and SIRT6 levels were associated with the risk of adverse pregnancy outcomes in PE patients (P<0.05). Conclusions There are differences in the expression levels of serum FGF-21 and SIRT6 between PE patients and healthy pregnant women. There is a certain correlation between the increasing trend of serum FGF-21 levels and the decreasing trend of SIRT6 and the risk of adverse pregnancy outcomes in PE patients.
